Challenges with approved targeted therapies against recurrent mutations in CLL: a place for new actionable targets
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author López-Oreja, Irene
- dc.contributor.author Playa-Albinyana, Heribert
- dc.contributor.author Arenas, Fabián
- dc.contributor.author López-Guerra, Mónica
- dc.contributor.author Colomer Pujol, Dolors
- dc.date.accessioned 2021-11-18T06:41:16Z
- dc.date.available 2021-11-18T06:41:16Z
- dc.date.issued 2021
- dc.description.abstract Chronic lymphocytic leukemia (CLL) is characterized by a high degree of genetic variability and interpatient heterogeneity. In the last decade, novel alterations have been described. Some of them impact on the prognosis and evolution of patients. The approval of BTK inhibitors, PI3K inhibitors and Bcl-2 inhibitors has drastically changed the treatment of patients with CLL. The effect of these new targeted therapies has been widely analyzed in TP53-mutated cases, but few data exist about the response of patients carrying other recurrent mutations. In this review, we describe the biological pathways recurrently altered in CLL that might have an impact on the response to these new therapies together with the possibility to use new actionable targets to optimize treatment responses.
- dc.description.sponsorship The group has been supported by the Spanish Ministry of Science and Innovation through the Plan Estatal de Investigación Científica y Técnica y de Innovación [RTI2018-094584-B-I00] and was cofounded by the European Regional Development Fund (ERDF) and the CERCA program from Generalitat de Catalunya, Centro de Investigación Biomédica en Cáncer (CIBERONC) and Generalitat de Catalunya [2017 SGR 1009].
- dc.format.mimetype application/pdf
- dc.identifier.citation López-Oreja I, Playa-Albinyana H, Arenas F, López-Guerra M, Colomer D. Challenges with approved targeted therapies against recurrent mutations in CLL: a place for new actionable targets. Cancers (Basel). 2021;13(13):3150. DOI: 10.3390/cancers13133150
- dc.identifier.doi http://dx.doi.org/10.3390/cancers13133150
- dc.identifier.issn 2072-6694
- dc.identifier.uri http://hdl.handle.net/10230/49007
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Cancers (Basel). 2021;13(13):3150
- dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/RTI2018-094584-B-I00
- dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword MAPK
- dc.subject.keyword NOTCH1
- dc.subject.keyword SF3B1
- dc.subject.keyword Chronic lymphocytic leukemia
- dc.subject.keyword Toll-like receptor (TLR)
- dc.title Challenges with approved targeted therapies against recurrent mutations in CLL: a place for new actionable targets
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion